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Abstract  
Introduction Defects in the DNA damage response (DDR) drive the 
development of cancer by fostering DNA mutation but also provide cancer-
specific vulnerabilities that can be exploited therapeutically. The recent 
approval of three different PARP inhibitors for the treatment of ovarian cancer 
provides the impetus for further developing targeted inhibitors of many of the 
kinases involved in the DDR, including inhibitors of ATR, ATM, CHEK1, 
CHEK2, DNAPK and WEE1.   
Areas covered We summarise the current stage of development of these 
novel DDR kinase inhibitors, and describe which predictive biomarkers might 
be exploited to direct their clinical use. 
Expert opinion Novel DDR inhibitors present promising candidates in cancer 
treatment and have the potential to elicit synthetic lethal effects. In order to 
fully exploit their potential and maximize their utility, identifying highly 
penetrant predictive biomarkers of single agent and combinatorial DDR 
inhibitor sensitivity are critical. Identifying the optimal drug combination 
regimens that could used with DDR inhibitors is also a key objective.  
 
 
 
Keywords: Cancer, Cell cycle, DNA damage response (DDR), Kinase 
inhibitors, Replication stress,  
 
  
Directing the use of DDR kinase inhibitors in cancer treatment                                                             3 
1 Introduction  
The genome is constantly exposed to a series of endogenous and exogenous 
agents that damage and alter the normal composition of the double helix [1]. If 
left unrepaired, the “DNA lesions” that are the result of this damage have the 
potential to either subtly alter cell behaviour by causing DNA mutations, or in 
extreme cases, to impair the fitness of cells. For example, unrepaired DNA 
damage can result in mutations that impair the ability to encode a fully 
functional transcriptome, thus impairing the fitness of cells. Likewise, DNA 
lesions that prevent DNA replication can lead to cell death, as can gross 
changes to the number and structure of chromosomes [1]. Given the level of 
threat to the genome and the potentially dire consequences of not repairing 
DNA damage once it occurs, it is unsurprising that relatively complex 
molecular networks that maintain the integrity of the genome have evolved. 
These networks are collectively known as the DNA damage response (DDR) 
[2]. Whilst a reductionist view of DDR networks might be that these operate by 
simply detecting and repairing DNA lesions, a more holistic understanding 
suggests that, like most other cellular processes, the DDR does not operate in 
isolation and interacts with, for example, DNA replication and transcriptional 
machinery [3], cell cycle control molecular networks [4], molecular pathways 
that control energy metabolism [5], programmed cell death [5], and systems 
that control innate immunity [6]. These interactions with ostensibly distinct 
molecular processes ensure, for example, that the cell cycle is stalled to allow 
DNA repair [4] or that cells with excessive levels of DNA damage are removed 
from the population. In doing so, the integrity of the genome within a single 
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cell is maintained, and that those cells that do divide, transmit a functional 
genome to daughter cells.  
 
Understanding how the DDR functions is an intense area of study, particularly 
from the perspective of how defects in the DDR influence cancer development 
and treatment. The link between defects in the DDR and cancer pathogenesis 
has been established via multiple lines of evidence. These include: (i) genetic 
studies, where defects in tumour suppressor genes that control the DDR (e.g. 
BRCA1, BRCA2, PALB2, RAD51C, RAD51D, FANC-family genes, MLH1, etc. 
(reviewed in [2])) predispose to familial forms of cancer; (ii) cytogenetic and 
genomic studies, where the number and type of different DNA mutations and 
forms of genomic instability found in human tumours often betray the DNA 
repair defects that have moulded tumour genomes [7]; and (iii) functional 
studies, where experimental induction of specific DNA repair defects causes 
cancer in animal models [8]. A straightforward hypothesis is that DNA 
mutations that result from DDR defects can, in some cases, allow cells to 
acquire the characteristics, or hallmarks, of cancer (e.g. ability to evade 
programmed cell death, independence from inhibitory growth signals etc. [9]). 
Moreover, DDR defects inevitably cause genetic diversity to emerge within a 
cell population and thus provide a likely driver for the molecular and 
phenotypic heterogeneity seen within tumours as well as the ability of tumour 
cell populations to evolve in the face of selective pressure [10]. The ability of 
DDR defects to result in disordered, mutated genomes might also be 
enhanced by commonly occurring defects in gatekeeper tumour suppressor 
genes such as p53, ATM, CHK1 and CHK2 [11]. These genes normally 
Directing the use of DDR kinase inhibitors in cancer treatment                                                             5 
encode proteins whose function is to induce cell cycle arrest in response to 
DNA damage; the partial or complete inactivation of these gatekeeper tumour 
suppressors often allows cells to circumvent cell cycle checkpoints and to 
continue to proliferate even in the face of persistent DNA damage (reviewed 
in [2]). Similarly, the inactivation of specific tumour suppressor proteins such 
as ATM (Ataxia telangiectasia mutated), allows cells to proliferate in the face 
of replication fork stress, i.e. the stalling or slowing of replication forks [12,13]. 
This replication fork stress appears to be a feature of pre-neoplastic lesions 
and is associated with the activation of oncogenes such as Cyclin E (CCNE1) 
or Myc. The hyper-activation of Cyclin E and Myc normally drives cells into a 
state of senescence [12,13] and whilst inactivation of ATM circumvents this 
event, the resultant cells divide with unresolved replication fork associated 
DNA damage [14]. As well as being driven by oncogene activation, replication 
fork stress can also arise through a variety of additional causes, including an 
excess of naturally occurring secondary structures within the DNA double 
helix, therapy induced DNA lesions that stall replication forks, nucleotide 
depletion, collisions between the replication and transcription machinery, or 
an enhanced incorporation of ribonucleotides into DNA [15]. In many cases, 
the replication fork stress that ensues can be tolerated so that it does not 
impair the fitness of cells (for example by inactivation of ATM as described 
above) but can lead to an increasingly disordered genome and often 
generates an increased reliance on DDR proteins such as ATR (Ataxia 
telangiectasia and Rad3-related protein) that are involved in stabilising 
replication forks [14]. 
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There is also a certain duality in how the DDR influences the real-world 
outcome for people with cancer; whilst defects in the DDR undoubtedly drive 
the development of cancer, these also provide somewhat cancer-specific 
vulnerabilities that often form the basis of how a patient might be best treated. 
For example, many of the chemotherapy or radiotherapy treatment regimens 
commonly used in the treatment of cancer generate DNA lesions, including 
abnormal covalent bonds (“cross links”) within the double helix. In tumour 
cells with particular DDR defects, these DNA lesions are ineffectively 
recognised and/or repaired, which often leads to cytotoxicity; conversely most 
normal cells, which in principle have a better capacity to process DNA 
damage, are relatively unharmed. Of course, highly proliferative normal 
tissues, such as the epithelial lining of the gastrointestinal tract and many 
myeloid cell lineages, are often not spared from the cytotoxic effect of 
chemotherapy treatment; the result for the patient receiving such treatment is 
often a series of deleterious side effects that significantly impair their quality of 
life. Nevertheless, in some patients, DNA damaging chemotherapy and/or 
radiotherapy can either extend survival or be curative, demonstrating that 
exploiting the DDR defects in tumour cells have real therapeutic value.    
 
The challenge of trying to develop what might be better tolerated treatment 
approaches for cancer that exploit DDR defects has, until now, largely been 
addressed by the discovery and development of targeted agents that either 
inhibit specific DNA repair or cell cycle checkpoint proteins. The central 
premise behind developing such targeted DDR inhibitors is that these might 
generate DNA lesions that selectively target any one of a number of 
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characteristics recurrently seen in tumour cells, including existing DDR 
defects (by exploiting synthetic lethal interactions), replication fork stress, 
genomic instability or existing defects in cell cycle control that prevent the 
effective repair of DNA damage. In addition, targeted DDR inhibitors might 
also show some utility when combined with other treatment modalities 
including combinations with DNA damaging chemotherapies, radiotherapy or 
immunotherapy, based partially on the assumption that such combinations will 
also elicit DNA lesions and/or a DNA damage response that is selectively 
cytotoxic to tumour cells [16]. 
 
In this review article, we summarise much of the recent data describing the 
discovery and development of novel targeted DDR kinase inhibitors. Arguably 
the first class of targeted DDR inhibitors to be approved for use in the 
treatment of cancer are the PARP inhibitors, including rucaprib (Clovis), 
olaparib (AstraZeneca) and niraparib (Tesaro), each of which is approved for 
the treatment of ovarian cancer [17]. As PARP inhibitors have recently been 
reviewed elsewhere [17], we focus here on inhibitors of kinases involved in 
the DDR: Ataxia telangiectasia mutated (ATM), Ataxia telangiectasia and 
Rad3-related protein (ATR), DNA Dependent Protein Kinase (DNA-PK) (all 
Phosphatidyl-Inositol Kinase-like Kinase (PIKK) enzymes [18]), CHK1, CHK2 
and WEE1. In each case, we will focus on a number of key issues we believe 
to be important to the eventual successful clinical development of these 
agents, namely: (i) what are the optimal predictive biomarkers that might 
predict favourable patient responses to each agent and what are the 
mechanisms of action that explain biomarker/drug sensitivity relationships 
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(Table 1); (ii) what mechanisms of drug resistance might be important for 
each target; (iii) what drug combination approaches might be appropriate for 
each drug class?  
 
2 ATM as a cancer drug target 
2.1 ATM function 
The PIKK family member Ataxia telangiectasia mutated (ATM) is activated at 
DNA double strand breaks (DSBs) and, amongst a number of substrates, 
phosphorylates the kinase CHK2 and the tumour suppressor p53 to activate 
the G1/S checkpoint [5] (Figure 1). ATM also activates CHK1 and CHK2 via 
phosphorylation to induce an intra-S or G2/M cell cycle arrest [19,20]. 
Additionally, ATM phosphorylates hundreds of other proteins associated with 
a wide variety of molecular processes including DNA repair, chromatin 
structure, transcription and apoptosis [5] (Figure 2). Like most kinases 
involved in the DDR, ATM also has “non-canonical” functions; these include 
the regulation of the spliceosome in the face of replication blocking lesions 
[21].  
 
ATM is a well-recognised tumour suppressor, and deleterious mutations 
and/or deletions in ATM are extremely common in several solid tumour types 
including gastric, colorectal and prostate cancers. In addition, several B-cell 
lymphoma subtypes including Mantle Cell Lymphoma (MCL) and chronic 
lymphocytic leukaemia (CLL), are characterised by high rates of ATM 
alterations, (50% in MCL [22]). Germ-line mutations in ATM results in Ataxia 
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Telangiectasia (A-T), a recessive disorder characterised by neural 
degeneration, ataxia and increased predisposition to cancer [5].  
 
2.2 ATM inhibitors 
The kinase activity of ATM can be inhibited using small molecule ATP 
analogues (Figure 2). KU55933, a potent and selective inhibitor of ATM, was 
developed by KuDOS pharmaceuticals (later acquired by AstraZeneca) [23]. 
This toolbox inhibitor does not possess all of the properties of a drug-like 
compound but nevertheless has utility in interrogating ATM function. Like its 
structural derivative KU60019 [24], the therapeutic potential of KU55933 is 
limited by poor aqueous solubility and in vivo bioavailability issues [25]. 
Another structurally related compound, KU59403, has improved bioavailability 
and solubility and also increased selectivity for ATM, compared to the 
structurally related PIKKs such as ATR and DNA-PK [26]. AstraZeneca has 
also recently initiated phase I clinical trials of another ATM inhibitor, AZD0156 
[27], used either as a single agent or in combination with the PARP inhibitor 
olaparib (NCT02588105 – clinicaltrials.gov), suggesting that drug-like ATM-
inhibitors can be developed.  
 
2.3 Combination therapy with ATM inhibitors: pre-clinical evidence 
In pre-clinical experiments, ATM inhibitors have been shown to be potent 
sensitizers to IR [23] (Table 2). In addition, ATM inhibitors have also been 
shown to increase the sensitivity of cells to topoisomerase II poisons 
(etoposide and doxorubicin) as well as to the radiomimetic bleomycin, agents 
which induce DNA DSBs [23,28]. ATM inhibitors also potentiate the toxicity of 
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topoisomerase I poisons such as camptothecin, which while they do not 
directly induce DNA DSB, do generate a covalent protein-DNA lesion that 
induces DSBs during S-phase as a result of collapsed replication forks [29].  
  
In response to DNA damage, ATM directly phosphorylates CtBP-interacting 
protein (CTIP), an endonuclease that initiates the 5’-3’ resection of DNA 
DSBs, a step critical for DSB repair by homologous recombination (HR) [30]. 
Given this, ATM-deficiency results in a mild homologous repair deficiency 
phenotype (HRD) [31], causing ATM-deficient cells to be sensitive to agents 
that target HR defect including cisplatin and PARP inhibitors (PARPi) [32,33]. 
This also suggests that ATM inhibitors might sensitise HR proficient cells to 
PARP inhibition or that ATM inhibitors could be used to potentiate the effect of 
PARPi.  
 
2.4 Biomarkers to predict ATM inhibitor sensitivity: preclinical evidence 
Biddlestone-Thorpe and colleagues demonstrated that exposure to KU60019 
induced greater radiation sensitivity in p53-mutant xenograft models 
compared to p53 wild type xenografts [34]. However, this p53-selective effect 
was not seen when KU59403 was assessed in in vitro studies or in xenografts 
[26]. It remains unclear whether these differences are due to the different 
inhibitors used and/or the different model systems used to assess 
radiosensitivity. In MCL, a B-cell lymphoma subtype, p53-defective tumour 
cell lines have also been shown to be more sensitive to the combination of 
ATMi and PARPi than their p53-proficient counterparts [35]. This finding thus 
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provides some support to the idea that a ATMi/PARPi combination should be 
assessed in p53-mutant MCL.   
 
ATM inhibitors could also be utilized to target tumour cells with loss of function 
mutations in genes previously shown to be synthetic lethal with ATM. For 
example ATM and ATR have been shown to be synthetic lethal, [36–38] 
suggesting that ATM inhibitors could be used in tumours with partial 
suppression of ATR function, although it is as yet unclear how this partial 
inactivation of ATR might be best measured in clinical biopsies. Furthermore, 
it has been demonstrated that BRCA1-deficient cells that have become PARP 
inhibitor resistant due to loss of either of two DNA repair proteins 53BP1 or 
REV7, can be resensitised to PARPi via exposure to an ATMi [39,40].  We 
also note that recently described CRISPR-based approaches to identify 
synthetic lethal approaches in human cells have identified a series of 
additional synthetic lethal (SL) interactions involving ATM that might be 
assessed as predictive biomarkers of ATM inhibitor sensitivity, including SL 
between ATM and CHK1, SETD2, SMO, KDM6A and VHL [41]. Thus far, no 
mechanisms of resistance to ATM inhibitors have been reported.  
 
3 ATR as a cancer drug target 
3.1 ATR function 
The PIKK Ataxia telangiectasia and Rad3-related protein (ATR) is activated 
by regions of single stranded (ss) DNA [42]. Such ssDNA can result from 
nucleolytic processing of DNA DSBs and is also found at stalled replication 
forks when the activity of the replicative DNA helicase (MCM complex) 
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becomes uncoupled from the activity of the DNA polymerase machinery [43]. 
Following activation, ATR phosphorylates a series of substrates, triggering a 
wide array of responses including the instigation of cell cycle checkpoints via 
CHK1 and WEE1 kinases, blocking replication origin firing, the repair of 
damaged DNA and also apoptosis [43] (Figure 1 and 3). CHK1 activates 
WEE1 via phosphorylation [44] and WEE1 in turn phosphorylates CDK1 (also 
known as CDC2) on tyrosine 15, thereby inhibiting CDK1 activity and 
preventing mitotic entry [45].  
 
3.2 ATR inhibitors 
Several specific, potent ATR small molecule inhibitors have been reported 
from both academic research groups as well as pharmaceutical companies 
including AstraZeneca, Bayer and Vertex Pharmaceuticals. The toolbox ATR 
inhibitor VE-821 (Vertex) is a competitive ATP analogue inhibitor of ATR 
which blocks in vitro kinase activity with a Ki of 6 nM and a greater than 600 
fold selectivity for ATR compared to ATM and DNA-PK [46]. The clinical ATR 
inhibitor VX-970 (previously VE-822, now M6620 since acquisition by Merck 
KGaA) is a structural analogue of VE-821 with superior potency, selectivity, 
and pharmacodynamic properties and as such was selected for clinical trial 
assessment [47]. Like the Vertex ATR inhibitors, the AstraZeneca toolbox 
ATR inhibitor AZ20 is a competitive ATP analogue inhibitor of ATR, which has 
an in vitro IC50 of 5 nM (50 nM in cell based assays) [48]. AZD6738 is an 
orally available analogue of AZ20 with superior solubility and 
pharmacodynamic properties [49], which is being used in clinical trials 
(including NCT01955668). In separate work, EPT-46464, developed by 
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Toledo et al., was identified as a potent and selective inhibitor of ATR by 
screening a library of small molecule inhibitors using a cell based assay for 
the ATR-dependent phosphorylation of histone H2AX [14]. NU6027, 
developed by Peasland et al. was originally developed as a CDK2 inhibitor. 
However this compound was subsequently discovered to potently inhibit ATR, 
with an IC50 of 6.7 μM [50]. Another ATR inhibitor that has recently entered 
the first stages of clinical testing as a monotherapy for the treatment of cancer 
is BAY1895344 (Bayer, see NCT03188965).  
 
3.3 Combination therapy with ATR inhibitors: pre-clinical evidence 
ATR inhibitors (ATRi) potently sensitize multiple tumour cell models to 
platinum-based cross-linking agents (e.g. cisplatin and oxalipaltin), PARP 
inhibitors, IR, UV light exposure, the chemotherapeutic gemcitabine and 
poisons of either topoisomerase I or II [47,50–54] (Table 2). Interestingly, VE-
821 also potentiates the toxicity of CHK1 inhibitors [55]. Importantly the 
synergy between VE-821 and cisplatin was much more pronounced in 
p53/ATM-deficient cancer cell lines compared to non-tumour cell lines, 
suggesting a potential tumour-specific biomarker for this drug combination 
[37]. An siRNA screen also found that silencing of the trans-lesion synthesis 
(TLS) polymerase ζ, consisting of REV3L and REV7, and the DNA DSB repair 
factor 53BP1, resulted in increased sensitivity to the VE-821/cisplatin 
combination [56]. Recurrent REV3L mutations have been identified in 
cisplatin-resistant squamous cell carcinoma of head and neck [57], making 
this a tumour subtype which might respond to the ATRi/cisplatin combination.  
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3.4 Biomarkers to predict ATR inhibitor sensitivity: preclinical evidence  
Several groups have identified candidate biomarkers of ATR inhibitor 
sensitivity. Using an RNA interference (RNAi)-based chemosensitisation 
screen, Mohni and colleagues found that the silencing of ATR itself, as well as 
many of the proteins required for ATR activation (ATRIP, RAD17, RAD9A, 
RAD1, HUS1, TOPBP1), profoundly sensitized cells to VE-821 [58]. In 
addition, loss of ATM or the nucleotide excision repair proteins ERCC1 and 
ERCC4 (XPF) sensitized cells to VE-821 [58]. The sensitivity of ATM-deficient 
cells to ATR inhibition has also been observed with the ATRi AZD6738 [48,59] 
and ATM-deficient MCL models were shown to be sensitive to ATR inhibitors 
[60]. 
 
In independent synthetic lethal screens, VE-821 was also found to selectively 
target cells deficient in the replicative polymerase component protein POLD1 
[61]. Although not mechanistically addressed, it seems likely that loss of 
POLD1 might cause increased replication stress resulting in a greater 
dependence on ATR activity. Similarly, a third synthetic lethal screen 
identified silencing of the chromatin-remodelling tumour suppressor gene 
ARID1A, to cause ATR inhibitor sensitivity, an effect later reproduced in 
multiple in vitro and in vivo models of ARID1A defective cancer [62]. 
Mechanistically, loss of ARID1A function results in a defect in the recruitment 
of the topoisomerase, TOP2A, to DNA; this TOP2A defect likely causes an 
inability to effectively decatenate DNA after replication and thus a reliance 
upon ATR  [62]. As ARID1A is commonly mutated in a large number of 
tumours, including uterine, stomach, bladder and ovarian clear cell 
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carcinomas [63], detecting tumour specific ARID1A mutations could provide a 
straightforward way to stratify patients for ATR inhibitor therapy.   
 
Recent pre-clinical studies in Ewing sarcoma (ES) and synovial sarcoma (SS) 
have also suggested that the pathognomonic EWS-FLI1/ERG and SS18-SSX 
gene fusions found in ES and SS, respectively, might also cause sensitivity to 
ATR inhibitors [64,65]. These cancer driver fusions, which are caused by 
chromosomal translocations, cause replication fork stress and a reliance upon 
ATR function; as a result ES and SS tumour cells and xenografts are 
profoundly sensitive to drug like ATR inhibitors [64,65]. Finally, cells that 
utilize the alternative form of telomere lengthening (ALT) also display 
increased sensitivity to VE-821 [66], suggesting that surrogate biomarkers of 
ALT could direct the use of ATRi. However, the generality of this observation 
was recently questioned by a study by Deeg and colleagues, who failed to 
observe ALT-specific ATRi sensitivities in a distinct set of tumour cell models 
[67], compared to those used to originally identify the ALT/ATRi phenotype 
[66]. This might suggest that whilst an ATRi-sensitivity phenotype might be 
associated with ALT, this effect might not be fully penetrant. 
 
3.5 Clinical trials 
VX-970 and AZD6738 are currently being evaluated in several on-going 
clinical trials; these include trials where ATR inhibitors are used either as 
single agents or in combination with standard of care chemotherapies 
(reviewed in [68]). Consistent with much of the preclinical development of 
AZD6738, the on-going clinical trials have largely focused on using ATM-
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deficiency as a biomarker for patient selection (eg. NCT02264678). This 
Phase I/Ib trial (NCT02264678) is also determining the safety of combining 
AZD6738 with carboplatin, the PARPi olaparib or the anti-PD-L1 antibody 
MEDI4736 in solid tumours. Treating cancers with PARPi might increase the 
number of stalled replication forks, making cells more reliant on ATR to 
maintain genomic integrity [69]. Treatment with ATR inhibitors could 
potentially make tumours more immunogenic by increasing their mutational 
load, potentially enhancing the effect of immune checkpoint inhibitors such as 
MEDI4736 [70].   
 
3.6 Resistance to ATR inhibitors 
A recent in vitro CRISPR (Clustered regularly interspaced short palindromic 
repeats)–Cas9 mutagenesis genetic perturbation screen demonstrated that 
loss of the cell-cycle control phosphatase, CDC25A, results in ATR inhibitor 
resistance [71] (see also the later section “CHK1 function“). In this particular 
case, loss of CDC25A elicits cell cycle arrest in ATRi exposed cells, prior to 
mitosis, reducing the DSB load that ATR inhibitors might otherwise generate 
[71]. This resistance-causing effect can be reversed by forcing mitotic entry 
using a WEE1 inhibitor [71]. It remains yet to be established whether loss of 
CDC25A will represent a clinically relevant mechanism of ATRi resistance, but 
if this this indeed the case, a combination of ATRi plus WEE1 inhibitor might 
provide a mechanism based approach to dealing with such an event.  
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4 DNA-PK as a cancer drug target 
4.1 DNA-PK function 
DNA-PK is a PIKK that consists of the DNA Dependent Protein Kinase 
catalytic subunit (DNA-PKcs) and the Ku70/Ku80 heterodimer. DNA-PKcs is 
an essential component of the canonical Non-Homologous End Joining 
(NHEJ) pathway [72]. NHEJ is required for the repair of DSBs as well as 
during the generation of antibody diversity in mature B-cells (class switch 
recombination (CSR)). During CSR, programmed DSBs are formed, which are 
repaired via NHEJ. The NHEJ defect caused by DNA-PKcs mutations likely 
contributes to the radiosensitivity and immunodeficiency observed in DNA-
PKcs mutant patients [73]. Conversely, elevated expression of DNA-PK is 
associated with radio-resistance in cervical and prostate cancer [74,75]. Apart 
from a role in NHEJ, DNA-PKcs has also been linked to telomere 
maintenance, transcription and several other functions [72] (Figure 4).  
 
4.2 DNA-PK inhibitors 
Currently there are two relatively specific DNA-PK inhibitors (DNA-PKi) in 
phase I clinical trials. MSC2490484A (M3814), developed by Merck KGaA, is 
being tested as a single agent in advanced solid tumours and CLL 
(NCT02316197) and in combination with fractionated palliative radiotherapy in 
solid tumours (NCT02516813). The reason for specific inclusion of CLL 
patients in the first clinical trial is because these patients often show deletion 
of the ATM gene [76], which is likely to be synthetically lethal with DNA-PK. 
VX-984 (M9831, developed by Vertex Pharmaceuticals and now licenced to 
Merck KGaA), is being tested as a single agent but also in combination with 
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pegylated liposomal doxorubicin in patients with solid tumours 
(NCT02644278). 
 
4.3 Biomarkers to predict DNA-PK inhibitor sensitivity: preclinical 
evidence 
Several synthetic lethal interactions have been described for DNA-PKcs. In an 
shRNA screen, Zhou et al. found that DNA-PKcs depletion is lethal in MYC-
dependent human cancers [77], primarily as DNA-PKcs inhibition leads to a 
reduction in MYC mRNA and protein expression, thus targeting MYC addicted 
tumour cells [77]. Defects in ATM and DNA-PKcs also form a synthetic lethal 
interaction, observed both in vitro as well as in vivo using a toolbox DNA-PK 
inhibitor [78]. A synthetic lethal interaction was also identified between DNA-
PKcs and the mismatch repair (MMR) protein MSH3. Dietlein et al. profiled 
mutations in 67 different cancer cell lines and found that mutations in MSH3, 
BRCA1, BRCA2 and other HR-associated genes correlated with DNA-PKcs 
addiction [79]. Exposure of MSH3-deficient cancer cells to the toolbox DNA-
PK inhibitor, KU60648 (KuDOS, AZ) lead to apoptosis. MSH3-deficient cells 
also displayed a reduction in HR, which might explain the synthetic lethality 
between MSH3 and DNA-PKcs. Additionally, a recent CRISPR screen for 
genetic interactions identified potential synthetic lethal interactions between 
DNA-PKcs (PRKDC) and: AKT1, CDK4, CDK9, CHK1, IGFR1, mTOR, VHL 
and RRM2 [41]; whether these synthetic lethal interactions can be replicated 
with small molecule DNAPK inhibitors remains to be seen. 
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Since DNA-PKcs is involved in NHEJ, a mechanism used to repair IR induced 
DSBs, a DNA-PK inhibitor could in principle be used to enhance the effect of 
radiotherapy. The maximum dose of radiotherapy applied is normally limited 
by normal tissue toxicity and some tumour cells are inherently more radio-
resistant. Therefore the addition of agents that enhance the effect of 
radiotherapy could improve tumour response. However, currently most 
improvements in radiotherapy are made by technological advances that allow 
more precise targeting of the radiation to the location containing the tumour 
based on anatomical information [80]. Still, for some tumours in difficult to 
reach areas, treatment with a DNA-PK inhibitor might improve treatment 
outcome. A potential disadvantage of such an approach is that the DNA-PK 
inhibitor, delivered systemically, might increase tumour radio-sensitivity but 
also the deleterious side effects of radiation in normal, surrounding, tissue. 
Finally, as far as we are aware, mechanisms of resistance to DNA-PK 
inhibitors, either used a single agents or in combination, have not as yet been 
identified in pre-clinical studies.  
 
4.4 Combination therapy with DNA-PK inhibitors: pre-clinical evidence 
DNA-PK inhibitors could be used to enhance agents that cause DSBs that 
require NHEJ for their repair, including topoisomerase II inhibitors etoposide 
or doxorubicin, or IR (Table 2). Combination of the toolbox DNA-PKi KU60648 
with etoposide resulted in increased survival of mice with Eμ:Myc;Arf−/−-driven 
lymphomas expressing an shRNA targeting Atm, providing proof of principle 
that such an approach might be feasible [78].  
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DNA-PKi could potentially limit mutational processes, especially in HR-
defective cancers. In these cancers, DSBs are repaired via NHEJ and other 
non-conservative pathways; this leads to deletions, translocations and other 
chromosomal rearrangements [81]. One hypothesis is that these alterations 
fuel cancer development, metastasis and resistance. Inhibition of DNA-PK 
could prevent NHEJ and therefore potentially limit the mutational burden. This 
might raise the possibility of using DNA-PK inhibitors to prevent tumorigenesis 
in patients at high risk of developing HR-defective cancers, such as those with 
BRCA1 or BRCA2 mutations. Such an approach might be relevant if 
prophylactic use of a DNA-PK inhibitor could be shown to be non-toxic.  
 
5 CHK1 as a cancer drug target 
5.1 CHK1 function 
ATR, but also ATM, phosphorylates and activates the kinase CHK1 in 
response to DNA damage [82] (Figure 1). CHK1 regulates the intra-S 
checkpoint via phosphorylation of CDC25A. This phosphorylation results in 
degradation of CDC25A and a subsequent reduction in CDK2 activity in S-
phase [83]. CHK1 also phosphorylates CDC25C and WEE1, events which 
control mitotic entry and thereby the G2/M checkpoint [84].  
 
5.2 CHK1 inhibitors 
The most specific CHK1 inhibitors that have reached the stage of clinical 
testing (used either as single agents or in combination with antimetabolites) 
include LY2603618 (Eli Lilly), SCH900776 (MK-8776; Merck KGaA), GDC-
0575 (Genentech), and CCT245737 (SRA373, Sierra Oncology) (reviewed in 
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[4,68]). Tumour types included in these phase I/II clinical trials include non-
small cell lung cancer (NSCLC) (NCT01139775), Acute Myeloid Leukaemia 
(AML) (NCT01870596), lymphoma (NCT01564251) as well as a range of 
other types of tumours (NCT02797977, NCT02797964). Although some of 
these studies are still on-going, recent results suggest early evidence of 
clinical efficacy of CHK1 inhibitors in subsets of patients and hint at certain 
histological subtypes that may be more sensitive to CHK1 inhibitors than 
others, such as NSCLC [85] and AML [86]. 
 
5.3 Biomarkers to predict CHK1 inhibitor sensitivity: preclinical evidence 
Although results from clinical trials show the clinical potential of CHK1 
inhibitors, particularly in combination with antimetabolites, they also underline 
the need for patient stratifying biomarkers. Various in vitro studies have 
shown that CHK1 inhibition allows selective targeting of p53-mutant cells, and 
CHK1 inhibition also potentiates the cytotoxicity of topoisomerase inhibitors 
and IR in p53-deficient, but not in p53-proficient cells [87–89]. However, other 
recent studies, including clinical studies, report no clear correlation between 
p53-deficiency and response to CHK1 inhibitors [90].  
 
H2AX and CHK1 phosphorylation have been used as predictive 
pharmacodynamic biomarkers of CHK1 inhibitor-chemotherapy combination 
sensitivity, including combinations of CHK1 inhibitors with gemcitabine or 
camptothecin [91]. pCHK1 (S296) was identified as a predictive biomarker of 
CHK1 inhibitor sensitivity in ovarian and ER/PR/HER2-negative (triple-
negative) breast cancers and H2AX was predictive in another breast cancer 
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subtype, luminal breast cancer [92]. In addition to CHK1 and γH2AX 
phosphorylation, Cyclin B1 levels were found to be an efficacy-predicting 
biomarker for CHK1 inhibitors [93], and a subset of cancer cell lines showed 
acute sensitivity to the CHK1 inhibitor MK-8776 as mono-therapy due to 
CDK2 activation in S-phase [94].  
 
5.4 Combination therapy with CHK1 inhibitors: pre-clinical evidence 
In addition to combinations with antimetabolites or other classes of cytotoxic 
agents (e.g. gemcitabine and topoisomerase inhibitors that synergise with 
CHK1 inhibitors [87,95]), a number of other CHK1 inhibitor combination 
approaches have been identified in pre-clinical models (Table 2). CHK1 
inhibition together with WEE1 inhibition has shown promising and strong 
synergistic activity in AML-derived leukemic cells [96] and in malignant 
melanoma tumour cell lines and xenografts [97]. In addition, a cancer-specific 
synthetic lethality between ATR and CHK1 kinase activities has been 
reported, suggesting tumours with reduced ATR activity could be sensitive to 
CHK1 inhibitors [55]. In combination with MK2 inhibitors, CHK1 inhibitors also 
target KRAS- or BRAF-mutant tumour cells [98].  
 
6 CHK2 as a cancer drug target 
6.1 CHK2 function 
The CHK2 kinase is primarily activated by ATM. After phosphorylation by 
ATM, CHK2 homo-dimerises [99]. Similar to CHK1, CHK2 also regulates the 
CDC25 family of phosphatases and affects the intra-S as well as the G2/M 
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checkpoint [20]. Additionally CHK2 also affects the G1/S checkpoint by 
phosphorylating CDC25C [100] (Figure 1).  
 
6.2 CHK2 inhibitors 
At the moment two relatively specific toolbox CHK2 inhibitors are used in pre-
clinical studies: PV1019  (NIH) [101] and CCT241533 (ICR) [102]. PV1019 is 
an ATP-competitive inhibitor that is reported to be selective for CHK2 and that 
synergises with topotecan, camptothecin, and IR in human tumour cell lines 
[101]. CCT241533 also binds the ATP-binding pocket in CHK2 and prevents 
CHK2 autophosphorylation at Serine 516 [103]. This CHK2 inhibitor does not 
synergise with gemcitabine, etoposide, or mitomycin C, but does enhance the 
effect of the PARP inhibitors rucaparib and olaparib [103].  
 
The kinase domains in CHK1 and CHK2 are highly conserved and AZD7762 
(AstraZeneca) targets CHK1 and CHK2 with similar potency [104]. In vivo, 
AZD7762 enhanced the effect of the topoisomerase I inhibitor irinotecan in a 
colon cancer xenograft model [104]. In a pancreatic tumour model, AZD7762, 
when used with gemcitabine, sensitized tumour cell lines and patient derived 
xenografts (PDX) to IR [105]. So far, three clinical trials with AZD7762 have 
been initiated, one of which has been completed and two have been 
terminated (NCT00937664, NCT00413686, NCT00473616). No further 
development of AZD7762 appears to be planned, possibly due to the cardio-
toxicity associated with this inhibitor [106]. Whether this cardio-toxicity is an 
on-target effect of AZD7762 and a potentially a common characteristic of 
CHK1 inhibitors is not clear from current data and remains to be investigated. 
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7 WEE1 as a cancer drug target 
7.1 WEE1 function 
CHK1 actives the kinase WEE1 via phosphorylation [44] and WEE1 in turn 
phosphorylates CDK1 (also known as CDC2) on Tyrosine 15 (Y15), thereby 
inhibiting CDK1 activity and preventing mitotic entry [45] (Figure 1). To allow 
mitosis to occur, WEE1 is phosphorylated by Polo-like Kinase 1 (PLK1), which 
triggers WEE1 degradation [107]. 
 
At present there is only one WEE1 inhibitor being tested in phase I and II 
clinical trials. AZD1775 (MK1775, Merck KGaA, now AstraZeneca) inhibits the 
tyrosine 15 phosphorylation on CDK1 and the G2/M checkpoint. WEE1 
inhibition forces cells into mitosis before replication has been completed, 
resulting in abnormal mitoses being formed and in some cases, apopotosis 
[108]. In head and neck cancer, patients with p53 mutations often respond 
poorly to cisplatin treatment. Osman et al. showed that platinum-resistant cell 
lines and xenografts could be sensitized to cisplatin by AZD1775 [109].  
 
7.2 Biomarkers to predict WEE1 inhibitor sensitivity: preclinical 
evidence 
Several potential biomarkers for AZD1775 sensitivity have been proposed. In 
in vitro studies, mutations in p53 sensitize tumour cells to WEE1 inhibition 
[110]. Loss of p53 function abrogates the G1 checkpoint and one hypothesis 
suggests that the greater reliance upon the G2/M cell cycle checkpoint can be 
targeted in p53 defective cells with WEE1 inhibitors. In p53-mutant cells, 
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elevated expression of Histone-lysine N-methyltransferase Enhancer of zeste 
homolog 2 (EZH2) and the mitotic cyclins (Cyclin B1, B2 and E1) also results 
in an increased reliance on WEE1 to prevent pre-mature mitotic entry [108]. 
Lower expression of PKMYT1, a kinase that regulates mitotic entry, also 
sensitizes cells to WEE1 inhibition [111]. Additionally, Weisberg et al. found 
that AZD1775 potentiates mTOR inhibition in NRAS- and KRAS-mutant 
positive AML cell lines and primary patient samples [112]. Pancreatic cancer 
cell lines with defects in DDR genes such as FANCC, FANCG and BRCA2 
are also more sensitive to AZD1775 [113]. Lastly, it has been shown that 
AZD1775 can inhibit H3K36me3-deficient tumour cells and in vivo tumours 
[114]. H3K36me3 is required to facilitate expression of Ribonucleoside-
diphosphate reductase subunit M2 (RRM2). RRM2 catalyses the synthesis of 
deoxyribonucleotides from ribonucleotides, which are required for DNA 
synthesis. WEE1 inhibition results in the degradation of RRM2 and in 
H3K36me3-deficient cells, the degradation of the already low level of RRM2 
results in dNTP (deoxyribonucleotide triphosphate) starvation and ultimately 
cell death.  
 
7.3 Combination therapy with WEE1 inhibitors: pre-clinical evidence 
WEE1 inhibition has been shown to synergise with CHK1 inhibition 
independently of p53 status [115] (Table 2). The combination has been shown 
to be effective in MCL cell lines [116] and in breast cancer cells [108]. 
Combinations with other DNA damaging or targeted agents, such as the 
HDAC inhibitor panobinostat, which down-regulates CHK1 [117], cytarabine, 
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which interferes with DNA synthesis [118] or cisplatin [119], have been 
investigated as well. 
 
While tumours with mutations in BRCA1 and BRCA2 are highly sensitive to 
PARP inhibitors, secondary “reversion” mutations in these genes restore 
some DNA repair function and cause PARP inhibitor resistance, in both pre-
clinical models and in the clinic [120,121]. Dréan et al. recently found that 
whilst tumour cells with reversion mutations are profoundly resistant to 
multiple PARP inhibitors, they still retain the AZD1775 sensitivity seen in 
tumour cells without reversions [122]. In mice bearing xenografts consisting of 
both BRCA2 revertant and non-revertant tumour cells, the PARP inhibitor 
olaparib had little therapeutic effect as it targeted non-revertant cells but not 
revertant tumour cells which eventually dominated the tumour cell population 
[122]. Conversely, treatment with AZD1775 extended the survival of mice as it 
effectively targeted both revertant and non-revertant tumour cells [122], 
raising the clinically testable hypothesis that WEE1 inhibitors could serve 
some utility in either delaying the onset of PARPi resistance or targeting 
resistant disease once it emerges.  
 
7.4 Clinical trials using WEE1 inhibitors 
Currently twenty-eight clinical trials with MK1775/AZD1775 are registered 
(reviewed in [68]) and at this point in time, the results of two phase I trials and 
one phase II trial have been reported. So far, two partial responses to 
AZD1775 as a single agent have been observed in patients with either 
BRCA1 or BRCA2 mutations [123]. In a follow-up phase II study, one patient 
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showed a prolonged complete response to AZD1775 [124]. This patient, 
diagnosed with serous ovarian cancer, had mutations in p53, BRCA1, MYC 
and Cyclin E.  
 
7.5 Mechanisms of WEE1 inhibitor resistance 
In vitro, one mantle cell leukemia (MCL)-derived cell line has been described 
that is resistant to both the CHK1 inhibitor PF-00477736 and AZD1775 [125]. 
MCL is characterized by Cyclin D1 overexpression and resistant cells 
exhibited a decrease in Cyclin D1 expression, as well as an upregulation of 
pro-survival pathways [125]. Another possible mechanism of resistance could 
be the restoration of the G1 checkpoint via restoration of p53 function. Li et al. 
found that inhibition of MDM2 with nutlin, resulting in activation of p53, 
reduced the cytotoxic effects of AZD1775 in p53-proficient cell lines [126]. 
Reactivation of the G1 checkpoint could allow tumour cells to stall the cell 
cycle to repair DNA damage, thus reducing the cytotoxic effects of AZD1775.  
 
8. Conclusions  
As described above, the identification of predictive biomarkers, optimal drug 
combinations and mechanisms of drug resistance are as critical a part of the 
drug discovery and development process for DDR kinase inhibitors, as they 
should be for all new cancer drugs. It seems reasonable to think that the 
efforts to dissect each of these areas for the DDR kinase inhibitors that are 
already being assessed in clinical trials and those yet to enter first in human 
studies, will have a positive effect on streamlining and optimising the route 
towards eventual drug approval.  
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9 Expert Opinion 
Predictive biomarkers of sensitivity to DDR inhibitors. As for any anti-
cancer treatment, it seems reasonable to assume that identifying predictive 
biomarkers of sensitivity to DDR inhibitors will be critical to the successful use 
of these agents. As we have described above, some of the first steps have 
been taken to define such predictive biomarkers. In some cases, such as in 
the case of ATR inhibitors, pre-clinical work has identified candidate predictive 
biomarkers (e.g. ATM loss, ARID1A mutation, Ewings sarcoma translocation 
etc.) that could now be assessed in clinical trials. Nevertheless, there are still 
a number of areas clearly worthy of further investigation. These include:  
(i) more pre-clinical research is required to identify predictive 
biomarkers not only of single agent DDR inhibitor sensitivity but 
also for combination therapy involving DDR inhibitors. The 
assumption that factors that cause single agent DDRi sensitivity will 
also predict sensitivity to combination therapy, and visa versa, 
might not be wholly true and so an increased focus on identifying 
predictive biomarkers of DDR combination therapy response is 
required;  
(ii) at present, much of the focus on identifying predictive DDRi 
biomarkers has used a “forward translation” where candidate 
biomarkers are identified using pre-clinical approaches, informing 
the design or analysis of clinical trials. As the number of clinical 
trials involving DDRi increases, taking “reverse translation” 
approaches, where observations made in clinical trials are then 
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validated in pre-clinical experiments, should become an integral 
part of identifying and understanding predictive biomarkers; 
(iii) in pre-clinical experimental systems, replication fork stress is often 
associated with DDRi sensitivity. Replication fork stress (i.e. the 
slowing and stalling of replication forks), has many causes and 
likely encapsulates a broad range of molecularly diverse 
phenotypes, each of which might result in a different DDRi 
sensitivity effect. With this in mind, additional focus is required to 
define clinically measurable predictive biomarkers that are related 
to replication fork stress but which also define a specific DDRi (or 
other drug) sensitivity.  
 
Mechanisms of resistance. Based on what is understood about mechanisms 
of resistance to DNA damaging chemotherapies, other kinase inhibitors and 
the approved DDRi class, PARP inhibitors, it might be interesting to predict 
which mechanisms might cause resistance to novel DDR kinase inhibitors. 
Firstly, mutations in the catalytic domains of DDR kinases that allow catalysis 
in the presence of small molecule inhibitors might very well cause drug 
resistance (analogous to EGFR catalytic domain mutations that cause 
gefitinib and erlotinib resistance [127]). Secondary “revertant” mutations in 
synthetic lethal partners of DDRi kinase inhibitor targets might also cause 
drug resistance, in much the same way that revertant mutations in BRCA1 or 
BRCA2 cause PARP inhibitor resistance [120,121]. One might predict, for 
example, that resistance to ATM/ATR inhibitor synthetic lethality in ATM 
mutant cancers might be driven by revertant mutations in ATM that restore 
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ATM function. Of course, this mechanism would only operate if the continued 
fitness of tumour cells was not impaired by restoring ATM function. Analogous 
to this concept, additional alterations in proteins that restore DDR pathway 
function might also drive resistance to DDR kinase inhibitors, similar to 53BP1 
or REV7 defects restoring DSB resection and PARP inhibitor resistance in 
BRCA1 defective cells [17]. Again, taking the ATM/ATR inhibitor synthetic 
lethal effect as an example, one might expect restoration of ATM pathway 
function via elevated function of downstream ATM signalling components to 
cause ATRi resistance. Finally, alterations in cell cycle control proteins are 
likely candidates for mediating resistance, as illustrated by CDC25A loss of 
function causing ATR inhibitor resistance [71]. These predictions of course 
are predicated on prior knowledge, and we would still argue that taking 
relatively unbiased approaches (such as genetic perturbation screens) to 
uncover mechanisms of resistance are also likely to be informative as taking 
hypotheses-testing approaches.  
 
Novel drug combinations: combining DDR inhibitors with 
immunotherapy. In addition to the potential of using DDR inhibitors in 
combination regimens with other DDR inhibitors or with standard-of-care 
chemotherapy or radiotherapy treatments, some consideration might be given 
to identifying optimised approaches to using DDR inhibitors alongside 
immunotherapy agents including immune checkpoint inhibitors [68,70,128]. 
Transformed or malignant cells can be recognised and in some cases 
eliminated by the adaptive and innate immune response [129]. In many cases, 
however, tumours acquire the ability to suppress these anti-cancer immune 
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responses. For example, tumour cells inactivate T cells by expressing 
Programmed Death-Ligand 1 (PD-L1); interaction between PD-L1 on tumour 
cells and Programmed Death Receptor 1 (PD-1) on the surface of T cells 
drives T cell inactivation. This inactivation can be reversed by the use of anti-
PD-L1 therapeutic antibodies such as atezolizumab (Roche) or duvalumab 
(AstraZeneca), eliciting an anti-tumour cell immune response. Although there 
is a relative paucity of pre-clinical data describing the effectiveness of DDR 
inhibitor/immunotherapy combinations (largely, we presume because of the 
relative complexity of effectively modelling immunotherapy responses in pre-
clinical models), such an approach might offer several advantages. For 
example, if DDR inhibitors and immunotherapy agents demonstrate non-
overlapping mechanisms of action and therefore are less likely to display 
overlapping mechanisms of resistance, it might make sense to consider DDR 
inhibitor/immunotherapy combinations that do not necessarily elicit 
synergistic/supra-additive effects on tumour cells, but nevertheless extend 
survival. Secondly, DDR inhibitors might themselves either stimulate or 
enhance anti-tumour cell immune responses to the extent that DDR 
inhibitor/immunotherapy combinations are effective. For example, DNA 
damage is known to enhance signalling pathways that activate the innate 
immune response, including the the cGAS-STING pathway that monitors 
cytoplasmic DNA [130]; using DDR inhibitors to exacerbate forms of DNA 
damage that activate cGAS-STING signalling in a cancer-specific fashion 
might very well enhance the effectiveness of immune modulating therapies. 
Thirdly, DDR inhibitors might be used to enhance the mutational burden of 
tumours; this in turn might elevate the neo-antigen load, a likely determinant 
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of anti-tumour immune responses [131]. However, there is a potentially 
limiting factor that could also limit the potential of DDR 
inhibitor/immunotherapy combinations; it is possible that DDR inhibitors might 
increase the formation of mutations and neoepitopes in a relatively 
heterogeneous fashion, generating multiple subclones, each with a distinct 
neoepitope profile. In such a scenario, the absence of a relatively clonal 
neoepitope might result in an anti-cancer immune response that only removes 
a minority of tumour cells. 
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Article highlights box 
 
 Inhibitors of the DDR kinases ATM, ATR, DNA-PK, CHK1, CHK2 and 
WEE1 are now being assessed in phase I and phase II clinical trials for 
the treatment of cancer.  
 These novel DDR inhibitors (DDRi) have the potential to exploit 
synthetic lethal interactions that operate in tumour cells, as well as 
exploiting other commonly found hallmarks of cancer, including 
genomic instability and replication fork stress  
 Pre-clinical studies have identified a series of candidate predictive 
biomarkers of sensitivity to DDRi, some of which are suitable for 
assessment in clinical trials.  
 Thus far, few mechanisms of DDRi resistance have been identified, 
although such effects seem likely 
 Drug combination strategies might be used to enhance the overall 
effectiveness of DDRi, but as for single agent DDRi use, predictive 
biomarkers are required to direct the use of combination approaches 
 
  
Directing the use of DDR kinase inhibitors in cancer treatment                                                             35 
Figure 
Figure 1 DDR pathway overview and candidate predictive biomarkers A) 
Ataxia-telangiectasia mutated (ATM) is recruited to and activated at DNA 
Double Strand Breaks (DSBs). Once activated, ATM phosphorylates p53 and 
CHK2, resulting in a G1/S cell cycle arrest via CDC25A and Cyclin-CDK 
(Cyclin-dependent kinase) complexes. Ataxia-telangiectasia and Rad3-related 
(ATR) is activated at persistent stretches of single strand DNA (ssDNA) 
coated by Replication Protein A (RPA); such ssDNA stretches occur at sites 
of resection or stalled replication forks. ATR primarily activates CHK1. CHK1 
can signal via CDC25A to activate the intra S checkpoint or via CDC25A and 
WEE1 to activate the G2/M checkpoint, depending on the phase of the cell 
cycle the damage is detected in. DNA dependent protein kinase (DNA-PK), 
activated at DSBs, does not play a role in the regulation of cell cycle 
progression after DNA damage. Kinases discussed in this review are 
highlighted in red. Dashed arrows indicate indirect regulation. B) Candidate 
predictive biomarkers for ATM, ATR, DNA-PK, CHK1 and WEE1 discussed in 
this review. ALT: Alternative lengthening of telomeres.  
 
Figure 2 ATM function and ATM inhibitors. A) ATM can be activated by 
hypoxia, reactive oxygen species (ROS), DNA double strand breaks (DSBs) 
or other types of DNA damage. Activated ATM phosphorylates multiple 
substrates and primary roles for ATM are illustrated, with key substrates 
indicated below. B) The structure of ATM inhibitors discussed in this review.  
 
Figure 3 ATR function and ATR inhibitors. A) Oncogene activation, 
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collisions between the transcription and replication machinery, DNA damage 
and dNTP starvation are all causes of replication stress. A characteristic of 
replication stress is the presence of stalled replication forks. At these stalled 
forks the exposed ssDNA is covered by RPA. ATR interacting protein (ATRIP) 
binds to RPA coated ssDNA and recruits ATR to the site of ssDNA. RAD17, 
the Rad9–Rad1–Hus1 (9-1-1) complex and (DNA) topoisomerase II binding 
protein 1 (TOPBP1) are also recruited and all these proteins are required for 
ATR activation. ATR can also be activated via Ewing Tumour Associated 
Antigen 1 (ETAA1), which interacts directly with RPA coated ssDNA. Once 
activated, ATR can arrest the cell cycle via CHK1, initiate DNA repair, 
facilitate the stabilization of stalled forks and/or inhibit the firing of new origins 
to prevent further fork stalling. Below each function of ATR key substrates are 
shown. B) ATR inhibitors described in the main text are shown and the main 
consequences of ATR inhibition are listed.  
 
Figure 4 DNA-PKcs function and DNA-PK inhibitors. A) DNA-PKcs 
primarily plays a role in non-homologous end joining (NHEJ). DNA-PKcs has 
also been shown to play a role in transcription via p53 and SP1. DNA-PKcs 
interacts with Polo-like kinase 1 (PLK1) and protein phosphatase 6 (PP6), 
both of which play a role in mitosis. Upon infection with Herpes Simplex virus, 
DNA-PKcs is degraded, while upon HIV infection, DNA-PKcs is activated to 
mediate p53-dependent apoptosis. DNA-PKcs is also required for telomere 
protection, together with KU70 and KU80. B) The structure of DNA-PK 
inhibitors discussed in the main text. 
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List of abbreviations 
53BP1 TP53-binding protein 1 
AKT1  RAC-alpha serine/threonine-protein kinase 
ALT  Alternative Lengthening of Telomeres 
AML  Acute Myeloid Leukaemia 
Arf  Tumor suppressor ARF  
ARID1A AT-rich interactive domain-containing protein 1A 
ATM  Ataxia telangiectasia mutated 
ATMi  ATM inhibitor 
ATP  Adenosine Triphosphate 
ATR  Ataxia telangiectasia and Rad3-related protein 
ATRi  ATR inhibitor 
ATRIP ATR Interacting Protein 
BRCA1 Breast cancer type 1 susceptibility protein 
BRCA2 Breast cancer type 2 susceptibility protein 
CCNE1 Cyclin E1 
CD8  T-cell surface glycoprotein CD8  
CDC2  CDK1 
CDC25A M-phase inducer phosphatase 1 
CDC25C M-phase inducer phosphatase 3 
CDK1  Cyclin-dependent Kinase 1 
CDK2  Cyclin-dependent Kinase 2 
CDK4  Cyclin-dependent Kinase 4 
CDK9  Cyclin-dependent Kinase 9 
CHK1  Checkpoint kinase-1 
CHK1i  CHK1 inhibitor 
CHK2  Checkpoint kinase-2 
CHK2i  CHK2 inhibitor 
CLL  Chronic Lymphocytic leukaemia 
CRISPR Clustered regularly interspaced short palindromic repeats 
CSR  Class Switch Recombination 
CTIP  CtBP-interacting protein 
CTLA-4 Cytotoxic T-lymphocyte protein 4 
DDR  DNA Damage Response 
DNA  Deoxyribonucleic Acid 
DNA-PK DNA-dependent Protein Kinase 
DNA-PKcs DNA-dependent Protein Kinase catalytic subunit 
DNA-PKi DNA-PK inhibitor 
dNTP  Deoxyribonucleotide triphosphate 
DSB  Double Strand Break 
dsDNA Double stranded DNA 
EGFR  Epidermal growth factor receptor 
ERCC1 Excision Repair Cross-Complementation Group 1 
ERCC4 Excision Repair Cross-Complementation Group 4 
EZH2  Enhancer of zeste homolog 2 
FANC  Fanconi anemia 
FANCC Fanconi anemia group C protein 
FANCG Fanconi anemia group G protein 
H2AX  Histone H2A.X 
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HDAC  Histone Deacetylase 
HR  Homologous Recombination 
HRD  Homologous Recombination Deficiency 
IGFR1 Insulin-like growth factor I 
IR  Ionising Radiation  
KDM6A Lysine-specific demethylase 6A 
KRAS  Kirsten rat sarcoma viral oncogene  
MCL  Mantle Cell Lymphoma 
MDM2 Double minute 2 protein 
MHC  Major histocompatibility complex 
MK2  MAP kinase-activated protein kinase 2 
MLH1  MutL protein homolog 1 
MMC  Mitomycin C 
MMR  Mismatch repair 
MSH3  MutS Homolog 3 
mTOR Mechanistic target of rapamycin 
NHEJ  Non-homologous end joining 
NKG2D Natural Killer Group 2, member D 
NKT  Natural Killer T-cell 
NSCLC Non-Small Cell Lung Cancer 
PARP  Poly ADP ribose polymerase 
PARPi PARP inhibitor 
PD1  Programmed cell death protein 1 
PDL1  Programmed death-ligand 1  
PIKK  Phosphatidyl inositol 3’ kinase-related kinases 
PKMYT1 Protein Kinase, membrane associated tyrosine/threonine 1 
PLK1  Polo-Like Kinase 1 
POLD1 Polymerase D1 
RAD1  RAD1 checkpoint DNA exonuclease 
RAD17  RAD17 checkpoint Clamp Loader component 
RAD9A RAD9 checkpoint Clamp component A 
RAD51C DNA repair protein RAD51 homolog 3 
RAD51D DNA repair protein RAD51 homolog 4 
REV3L REV3 like, DNA directed polymerase zeta catalytic subunit 
REV7  MAD2L2: Mitotic Arrest Deficient 2 like 2 
RNA  Ribonucleic Acid 
RRM2  Ribonucleoside-diphosphate reductase subunit M2 
SETD2 SET domain-containing protein 2 
SMO  Smoothened homolog 
ssDNA Single Stranded DNA 
TLS  Trans Lesion Synthesis 
TOP2A Topoisomerase IIA 
TOPBP1 DNA topoisomerase 2-binding protein 1 
UV  Ultraviolet (light) 
VHL  Von Hippel-Lindau disease tumor suppressor 
WEE1  WEE1 G2 checkpoint kinase 
WEE1i WEE1 inhibitor 
XPF  Xeroderma Pigmentosum, complementation group F 
γH2AX H2AX phosphorylated at S139 
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Table 1: Candidate predictive biomarkers identified from pre-clinical studies  
 
Drug Candidate biomarker 
ATM inhibitor p53 status [26,34,35] 
ATR deficiency [36–38] 
Potential synthetic lethal interactions between ATM and 
VHK1, SETD2, SMO, KDM6A, VHL [41] 
ATR inhibitor Silencing of ATRIP, RAD17, RAD9A, RAD1, HUS1, TOPBP1, 
XPF, ERCC1 [58] 
ATM deficiency [36,48,59]  
POLD1 deficiency [61] 
ARID1A deficiency [62] 
Alternative lengthening of telomeres [66,67] 
EWS-FLI1/ERG Ewing sarcoma fusion gene [64]  
SS18-SSX synovial sarcoma fusion gene [65] 
ATR inhibitor + 
Cisplatin 
combination 
Silencing of 53BP1, REV3L or REV7 [56] 
DNA-PK inhibitor Potential synthetic lethal interactions between DNA-PK and 
AKT1, CDK4, CDK9, CHK1, IGFR1, mTOR, VHL1, RRM2 
silencing [41] 
ATM loss [78] 
CHK1 inhibitors p53 status [87–90] 
CHK1 inhibitors 
+MK2 inhibitors 
KRAS and BRAF-mutant tumours[98] 
WEE1 inhibitors p53 status [110] 
Increased expression of EZH2, Cyclin B1, B2 and E1[108] 
Low expression of PKMYT1[111] 
Defects in FANCC, FANCG and BRCA2 [113] 
H3K36Me3-deficiency [114] 
WEE1 inhibitors + 
mTOR inhibitors 
NRAS and KRAS- mutations [112] 
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Table 2: Drug combinations associated with each DDR kinase inhibitor  
Drug target Inhibitor Combination Stage of development 
ATM AZD0156 + olaparib Clinical trial phase I 
(NCT02588105) 
KU-55933 
 
+ IR or radiomimetic 
+ topoisomerase I poisons 
Pre-clinical data [23] 
ATR VE-821 + cisplatin Pre-clinical data [37] 
AZD6738 + carboplatin 
+ olaparib 
+ anti- PD-L1 antibody 
(MEDI4736) 
Phase I trial 
(NCT02264678) 
AZD6738 and 
VX970 
 
+ Standard chemotherapy Phase I trials  
(Reviewed in [68]) 
VX970 + cisplatin Pre-clinical data [65]  
+ olaparib Pre-clinical data [65] 
DNA-PK VX-984 + doxorubicin Phase I (NCT NCT02644278) 
CHK1 MK8776 
(SCH900776), 
LY2603618,  
CCT245737,  
GDC-0575 
+ Standard chemotherapy Phase I trials  
(Reviewed in [68]) 
+ WEE1 inhibitor Pre-clinical data [96,97] 
CHK2 PV1019 + topotecan 
+ camptothecin 
+ IR 
Pre-clinical data [101] 
CCT241533 + PARP inhibitors Pre-clinical data [103] 
CHK1/2 AZD7762 + irinotecan 
+ gemcitabine 
Pre-clinical data [104,105] 
WEE1 AZD1775 
 
+ CHK1 inhibition Pre-clinical data [105,108,115] 
+ cisplatin Pre-clinical data [119] 
+ cytarabine Pre-clinical data [118] 
+ panobinostat Pre-clinical data [117] 
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Abbreviations: IR = Ionizing radiation. 
 
 
 
